Aim Elexacaftor/tezacaftor/ivacaftor (ETI) has markedly improved cystic fibrosis (CF) outcomes. However, its long‐term impact on nutrition, metabolism and liver health remains underexplored. We assessed 30‐month changes in pulmonary, nutritional, metabolic and inflammatory markers in people with CF (PwCF) homozygous for F508del.
Nicola Perrotta +5 more
wiley +1 more source
Operationalising Article 13 of the Convention on the Rights of Persons with Disabilities the role of assistive technology in ensuring access to justice. [PDF]
McVeigh J.
europepmc +1 more source
Commentary on the <i>Final report on complaint no. 23.67; Tiffany Roy; (Timothy Kalafut, PhD; evaluation of biological/DNA results given activity level propositions)</i>. [PDF]
Roy T.
europepmc +1 more source
The Right to a Jury Trial in Actions for Patent Infringement and Suits for Declaratory Judgement [PDF]
Coggio, Brian D., DeMasi, Timothy E.
core +1 more source
How to bring generative AI to oncology practice. [PDF]
Truhn D, Kather JN.
europepmc +1 more source
Contracts for the international sale of goods:the significance of "fundamental breach" in the Vienna Convention, 1980 [PDF]
O'Neill, Maria
core
Clinical efficacy and influencing factors of intensity-modulated radiation therapy in the treatment of sinonasal cancer. [PDF]
Lu P, Guo R, Yang F, Zhao G.
europepmc +1 more source
Six solutions for clinical study data sharing in Germany. [PDF]
Bobrov E +4 more
europepmc +1 more source

